➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKinsey
McKesson
Express Scripts
Colorcon

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

VISTARIL Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Vistaril, and what generic alternatives are available?

Vistaril is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in VISTARIL is hydroxyzine hydrochloride. There are nineteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the hydroxyzine hydrochloride profile page.

Drug patent expirations by year for VISTARIL
Drug Prices for VISTARIL

See drug prices for VISTARIL

Drug Sales Revenue Trends for VISTARIL

See drug sales revenues for VISTARIL

Recent Clinical Trials for VISTARIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Colorado, DenverN/A
Stanford UniversityN/A

See all VISTARIL clinical trials

Pharmacology for VISTARIL
Drug ClassAntihistamine
Mechanism of ActionHistamine Receptor Antagonists

US Patents and Regulatory Information for VISTARIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer VISTARIL hydroxyzine pamoate CAPSULE;ORAL 011459-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Pfizer VISTARIL hydroxyzine hydrochloride INJECTABLE;INJECTION 011111-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Pfizer VISTARIL hydroxyzine pamoate CAPSULE;ORAL 011459-004 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
Pfizer VISTARIL hydroxyzine pamoate CAPSULE;ORAL 011459-006 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Pfizer VISTARIL hydroxyzine pamoate SUSPENSION;ORAL 011795-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Pfizer VISTARIL hydroxyzine hydrochloride INJECTABLE;INJECTION 011111-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKinsey
McKesson
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.